WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today reported financial results for the third quarter of 2006. The Company recorded total revenue of $12.4 million for the three months ended September 30, 2006 compared to $5.9 million for the three months ended September 30, 2005. Total revenues for the third quarter of 2006 included $4.3 million from ANTARA(R) (fenofibrate) capsules, $4.0 million in revenues related to FACTIVE(R) (gemifloxacin mesylate) tablets, $3.5 million in revenue from the Company’s recently concluded co-promotion partnership and a modest milestone payment from Pfizer S.A. de C.V. (Pfizer Mexico).
